Documentos relacionados

1. Identification of cough-variant asthma phenotypes based on clinical and pathophysiologic data.
2. Benralizumab affects NK cell maturation and proliferation in severe asthmatic patients.
3. Adverse events of anti-IL-5 drugs in patients with eosinophilic asthma: a meta-analysis of randomized controlled trials and real-world evidence-based assessments.
4. Real-life experience after 3 months with tezepelumab before marketing approval.
5. Pediatric and adult asthma clinical phenotypes: a real world, big data study based on acute exacerbations.
6. Comparative effectiveness of omalizumab, mepolizumab, and dupilumab in asthma: A target trial emulation.
7. Short-acting ß₂-agonist prescriptions are associated with poor clinical outcomes of asthma: the multi-country, cross-sectional SABINA III study.
8. Airway autoimmunity, asthma exacerbations, and response to biologics.
9. Novel mechanisms of action contributing to benralizumab's potent anti-eosinophilic activity.
10. What trials do and do not tell us about treatments for severe asthma.